Evidencebased interventional pain management techniques commonly used in clinical cancer pain

Abstract

Abstract:Cancer pain can seriously disturb patients′ quality of life. Intractable cancer pain not amenable to standard analgesics is a horrifying truth in parts of the patients. Interventional pain management techniques can be an effective alternative for those patients. Based on the evidence of evidencebased medicine, celiac plexus block or splanchnic nerve block are recommended for the management of upper abdominal cancer pain, pelvic cancer pain can be managed with superior hypogastric plexus block, and back pain due to vertebral compression fractures with tumor invasion can be managed with percutaneous vertebroplasty or kyphoplasty. Intercostal nerve block for chest wall cancer pain, ganglion impar block and saddle block for perineal pain due to pelvic tumors should be used only in the context of an experimental study or in cases of compassionate use with no other available forms of effective pain relief.

Key words:Neoplasms,Pain,Surgical procedures, minimally invasive

Ji Kai, Shao Yuejuan, Wang Kun. Evidencebased interventional pain management techniques commonly used in clinical cancer pain[J]. Journal of International Oncology, 2016, 43(10): 775-778.

References

［1］ Shao YJ, Ji K, Hao JL, et al. Nonpain symptom prevalence and intensity of inpatients with moderate to severe cancer pain in China［J］. Am J Hosp Palliat Care, 2016, 33(5): 448-455. DOI: 10.1177/1049909114565109. ［2］ Wong FC, Lee TW, Yuen KK, et al. Intercostal nerve blockade for cancer pain: effectiveness and selection of patients［J］. Hong Kong Med J, 2007, 13(4): 266-270. ［3］ Gulati A, Shah R, Puttanniah V, et al. A retrospective review and treatment paradigm of interventional therapies for patients suffering from intractable thoracic chest wall pain in the oncologic population［J］. Pain Med, 2015, 16(4): 802-810. DOI: 10.1111/pme.12558. ［4］ Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial［J］. JAMA, 2004, 291(9): 1092-1099. DOI: 10.1001/jama.291.9.1092. ［5］ Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer［J］. Am J Gastroenterol, 2007, 102(2): 430-438. DOI: 10.1111/j.15720241.2006.00967.x. ［6］ Zhang CL, Zhang TJ, Guo YN, et al. Effect of neurolytic celiac plexus block guided by computerized tomography on pancreatic cancer pain［J］. Dig Dis Sci, 2008, 53(3): 856-860. DOI: 10.1007/s1062000799052. ［7］ Wyse JM, Carone M, Paquin SC, et al. Randomized, doubleblind, controlled trial of early endoscopic ultrasoundguided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer［J］. J Clin Oncol, 2011, 29(26): 3541-3546. DOI: 10.1200/JCO.2010.32.2750. ［8］ Zhong W, Yu Z, Zeng JX, et al. Celiac plexus block for treatment of pain associated with pancreatic cancer: a metaanalysis［J］. Pain Pract, 2014, 14(1): 43-51. DOI: 10.1111/papr.12083. ［9］ Mercadante S, Klepstad P, Kurita GP, et al. Sympathetic blocks for visceral cancer pain management: a systematic review and EAPC recommendations［J］. Crit Rev Oncol Hematol, 2015, 96(3): 577-583. DOI: 10.1016/j.critrevonc.2015.07.014. ［10］ Suleyman ON, Talu GK, Camlica H, et al. Efficacy of coeliac plexus and splanchnic nerve blockades in body and tail located pancreatic cancer pain［J］. Eur J Pain, 2004, 8(6): 539-545. DOI: 10.1016/j.ejpain.2004.01.001. ［11］ Pello S, Miller A, Ku T, et al. Hemorrhagic gastritis and duodenitis following celiac plexus neurolysis［J］. Pain Physician, 2009, 12(6): 1001-1003. ［12］ Staats PS, Hekmat H, Sauter P, et al. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a doubleblind, randomized, placebocontrolled study［J］. Pain Med, 2001, 2(1): 28-34. DOI: 10.1046/j.15264637.2001.002001028.x. ［13］ Amr YM, Makharita MY. Comparative study between 2 protocols for management of severe pain in patients with unresectable pancreatic cancer: oneyear followup［J］. Clin J Pain, 2013, 29(9): 807-813. DOI: 10.1097/AJP.0b013e3182757673. ［14］ Kroll CE, Schartz B, GonzalezFernandez M, et al. Factors associated with outcome after superior hypogastric plexus neurolysis in cancer patients［J］. Clin J Pain, 2014, 30(1): 55-62. DOI: 10.1097/AJP.0b013e3182869d68. ［15］ Mishra S, Bhatnagar S, Rana SP, et al. Efficacy of the anterior ultrasoundguided superior hypogastric plexus neurolysis in pelvic cancer pain in advanced gynecological cancer patients［J］. Pain Med, 2013, 14(6): 837-842. DOI: 10.1111/pme.12106. ［16］ Plancarte RS, MayerRivera FJ. Radiofrequency procedures for sacral and pelvic region pain［J］. Pain Pract, 2002, 2(3): 248-249. DOI: 10.1046/j.15332500.2002.02031.x. ［17］贾和平, 金瑞林, 李英杰, 等. 经骶尾椎间盘穿刺毁损奇神经节对会阴部晚期癌痛患者的疗效［J］. 中华麻醉学杂志, 2008, 28(4): 376-377. DOI: 10.3321/j.issn:02541416.2008.04.012. ［18］ Candido K, Stevens RA. Intrathecal neurolytic blocks for the relief of cancer pain［J］. Best Pract Res Clin Anaesthesiol, 2003, 17(3): 407-428. ［19］ Slatkin NE, Rhiner M. Phenol saddle blocks for intractable pain at end of life: report of four cases and literature review［J］. Am J Hosp Palliat Care, 2003, 20(1): 62-66. ［20］ Anselmetti GC, Manca A, Montemurro F, et al. Percutaneous vertebroplasty in multiple myeloma: prospective longterm followup in 106 consecutive patients［J］. Cardiovasc Intervent Radiol, 2012, 35(1): 139-145. DOI: 10.1007/s0027001101114. ［21］ Chew C, Ritchie M, O′Dwyer PJ, et al. A prospective study of percutaneous vertebroplasty in patients with myeloma and spinal metastases［J］. Clin Radiol, 2011, 66(12): 1193-1196. DOI: 10.1016/j.crad.2011.08.004. ［22］Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus nonsurgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial［J］. Lancet Oncol, 2011, 12(3): 225-235. DOI: 10.1016/S14702045(11)700080. ［23］ Miller FG, Kallmes DF, Buchbinder R. Vertebroplasty and the placebo response［J］. Radiology, 2011, 259(3): 621-625. DOI: 10.1148/radiol.11102412. ［24］ Hulme PA, Krebs J, Ferguson SJ, et al. Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies［J］. Spine (Phila Pa 1976), 2006, 31(17): 1983-2001. DOI: 10.1097/01.brs.0000229254.89952.6b. ［25］ Mudano AS, Bian J, Cope JU, et al. Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a populationbased cohort study［J］. Osteoporos Int, 2009, 20(5): 819-826. DOI: 10.1007/s0019800807455. ［26］ Papanastassiou ID, Aghayev K, Berenson JR, et al. Is vertebral augmentation the right choice for cancer patients with painful vertebral compression fractures?［J］. J Natl Compr Canc Netw, 2012, 10(6): 715-719.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.